Thromboangiitis obliterans in two brothers

Li,Qi‑Lin; He,Dan‑Hua; Huang,Yong‑Hua; Niu,Mu

doi:10.3892/etm.2013.1160

Thromboangiitis obliterans in two brothers

Authors:
- Qi‑Lin Li
- Dan‑Hua He
- Yong‑Hua Huang
- Mu Niu
View Affiliations

Affiliations: Department of Dermatology, Fourth Affiliated Hospital of Jinan University, Guangzhou Red Cross Hospital, Guangzhou, Guangdong 510220, P.R. China
Published online on: June 14, 2013 https://doi.org/10.3892/etm.2013.1160
Pages: 317-320

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Two brothers (case 1 and case 2) with erythema nodosum were diagnosed with thromboangiitis obliterans (TAO). The patients were treated with compounds including Danshen Dripping Pills, Fufang Danshen Diwan and Salvia tetramethylpyrazine. The patients were also treated with fibroblast growth factor to promote epidermal growth and Bayaspirin enteric-coated tablets to reduce platelet aggregation. The polysaccharide nucleic acid fraction of Bacillus Calmette-Guérin and compound glycyrrhizin tablets were taken to improve immune function. Following treatment, case 2 had reduced pain levels in the left foot. The ulcer on the first toe of the left foot had decreased in size, with a reduction in pus secretions and inflammation. Case 1 demonstrated a reduction in pus secretion from the ulcer. However, the area of the ulcer had increased, spreading to the fifth toe with gangrene. A tendon had become exposed on the right foot, which was broken and induced severe pain.

View Figures

View References

1.	Małecki R, Zdrojowy K and Adamiec R: Thromboangiitis obliterans in the 21st century - a new face of disease. Atherosclerosis. 206:328–334. 2009.PubMed/NCBI
2.	von Winiwarter F: Über eine eigenthümliche form von endarteritis und endophlebitis mit gangrän des fusses. Arch Klin Chir. 23:202–206. 1879.(In German).
3.	Buerger L: Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci. 136:567–580. 1908. View Article : Google Scholar : PubMed/NCBI
4.	Kurata A, Nonaka T, Arimura Y, Nunokawa M, Terado Y, Sudo K and Fujioka Y: Multiple ulcers with perforation of the small intestine in Buerger’s disease: a case report. Gastroenterology. 125:911–916. 2003.PubMed/NCBI
5.	Arkkila PE: Thromboangiitis obliterans (Buerger’s disease). Orphanet J Rare Dis. 1:142006.
6.	Olin JW: Thromboagiitis obliterans (Buerger’s disease). N Engl J Med. 343:864–869. 2000.
7.	Pereira de Godoy JM and Braile DM: Buerger’s disease and anticardiolipin antibodies. J Cardiovasc Med (Hagerstown). 10:792–794. 2009.
8.	Olin JW, Young JR, Graor RA, Ruschhaupt WF and Bartholomew JR: The changing clinical spectrum of thromboangiitis obliterans (Buerger’s disease). Circulation. 82(Suppl): IV3–IV8. 1990.PubMed/NCBI
9.	de Godoy JM, de Godoy MF and Braile DM: Recurrent thrombosis in patients with deep vein thrombosis and/or venous thromboembolism associated with anticardiolipin antibodies. Angiology. 57:79–83. 2006.
10.	Patwa JJ and Krishnan A: Buerger’s disease (thromboangiitis obliterans) - Management by Ilizarov’s technique of horizontal distraction. A retrospective study of 60 cases. Indian J Surg. 73:40–47. 2011.
11.	Darnige L, Helley D, Fischer AM, Emmerich J, Smadja DM and Fiessinger JN: Platelet microparticle levels: a biomarker of thromboangiitis obliterans (Buerger’s disease) exacerbation. J Cell Mol Med. 14:449–451. 2010.PubMed/NCBI
12.	Lawall H, Bramlage P and Amann B: Treatment of peripheral arterial disease using stem and progenitor cell therapy. J Vasc Surg. 53:445–453. 2011. View Article : Google Scholar : PubMed/NCBI
13.	Lee T, Seo JW, Sumpio BE and Kim SJ: Immunobiologic analysis of arterial tissue in Buerger’s disease. Eur J Vasc Endovasc Surg. 25:451–457. 2003.PubMed/NCBI
14.	Slavov ES, Stanilova SA, Petkov DP and Dobreva ZG: Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol. 23:219–226. 2005.
15.	Eichhorn J, Sima D, Lindschau C, Turouski A, Schmidt H, Schneider W, Haller H and Luft FC: Antiendothelial cell antibodies in thromboangiitis obliterans. Am J Med Sci. 315:17–23. 1998. View Article : Google Scholar
16.	Saito Y, Sasaki K, Katsuda Y, Murohara T, Takeshita Y, Okazaki T, Arima K, Katsuki Y, Shintani S, Shimada T, et al: Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger’s disease. Circ J. 71:1187–1192. 2007.
17.	Wang Z, Liu LQ, Ling HZ and Yang JM: Value of serum anti-neutrophil cytoplasmic autoantibodies and anti-vascular endothelial cell antibodies in diagnosis of erythema nodosum. China Trop Med. 8:1554–1555. 2008.
18.	Takanashi T, Horigome R, Okuda Y, Nose M, Matsuda M and Ikeda S: Buerger’s disease manifesting nodular erythema with livedo reticularis. Intern Med. 46:1815–1819. 2007.
19.	Wysokinski WE, Kwiatkowska W, Maslowski L, Witkiewicz W and Kowal-Gierczak B: Buerger’s disease in two brothers: iliac artery occlusion by thromboangiitis obliterans - case reports. Angiology. 49:409–414. 1998.
20.	Chen Z, Takahashi M, Naruse T, Nakajima T, Chen YW, Inoue Y, Ishikawa I, Iwai T and Kimura A: Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger disease. Hum Genet. 122:367–372. 2007. View Article : Google Scholar : PubMed/NCBI
21.	Isner JM, Baumgartner I, Rauh G, Schainfeld R, Blair R, Manor O, Razvi S and Symes JF: Treatment of thromboangiitis obliterans (Buerger’s disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg. 28:964–973. 1998.